[A clinical experience in treatment with bevacizumab for unresectable colorectal cancer].
Bevacizumab, a humanized monoclonal antibody to VEGF for advanced recurrent colorectal cancer, has been known for complications of gastrointestinal perforation, hemorrhage, thromboembolism and proteinuria, as adverse effects. These findings must be taken care as well as adverse drug reactions (ADR) caused by combination chemotherapy. We here in present a clinical experience in treatment with bevacizumab for unresectable colorectal cancer. Six patients treated with bevacizumab for over two courses until April 2008 were analyzed for this study. PR was obtained in one case with mFOLFOX6. Even though, grade 3 neutropenia was observed in only one case with FOLFIRI, the other cases had grade 2 or less in ADR. In addition, there were no any specific ADRs related with bevacizumab, so we concluded that combination chemotherapy for advanced recurrent colorectal cancer with bevacizumab was well-tolerated.
Fujimoto
Takashi
T
Dept. of Surgery, Tokyo Women's Medical University Medical Center East.
Yoshimatsu
Kazuhiko
K
Yokomizo
Hajime
H
Umehara
Arihiro
A
Watanabe
Kiyo
K
Otani
Taisuke
T
Matsumoto
Atsuo
A
Osawa
Gakuji
G
Itagaki
Hiroko
H
Ogawa
Kenji
K
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D014057:Tomography, X-Ray Computed
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab